GENETIC TECHNOLOGIES LIMITED — Board/Management Information 2012

Dec 9, 2012

==> picture [595 x 69] intentionally omitted <==

==> picture [595 x 69] intentionally omitted <==

ASX ANNOUNCEMENT December 10[th] , 2012

Appointment of permanent CEO and Non-Executive Director

Appointment of permanent CEO

The Board of Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) wishes to announce that, further to the Company’s announcement dated November 28[th] , 2012, Ms. Alison Mew has been appointed as the permanent Chief Executive Officer of Genetic Technologies Limited.

GTG Chairman, Dr. Mal Brandon said “The Board is extremely pleased that Ms. Mew has accepted the Company’s offer to become its permanent CEO. In her previous role as GTG’s Chief Operating Officer, a position she held for more than three years, she played a key role in the establishment of the Group’s US operations along with securing the Australian laboratory’s US compliance. We are confident that she is well placed to lead the Company through its next stages of development in both the Australian and US markets.”

Appointment of Non-Executive Director

The Board is also pleased to announce the appointment of Mr. Ben Silluzio as a Non-Executive Director of the Company.

Mr. Silluzio, 36, specialises in the provision of advice for sophisticated investors, institutional clients and high net worth families in Melbourne, nationally and abroad. Currently, he serves as the managing partner and desk head of RBS Morgans Family Office, and is also a director of Private Branded Beverages Ltd., a public unlisted company, and is a former President and Chairman of the Italian Chamber of Commerce. Previously, Mr. Silluzio has held several senior positions in the stockbroking and funds management industries, including: Director of UBS Wealth Management Australia, Senior Vice President of Credit Suisse First Boston in Melbourne, Vice President and member of the “Smith Barney Century Council” at Citigroup Smith Barney in Melbourne and as an institutional client advisor at Colonial Institutional Stockbroking in Sydney and Melbourne.

Dr. Mal Brandon said “The Board is pleased to welcome Mr. Silluzio to the Company’s Board. We are confident that he will bring valuable skills, contacts and experience which will assist the Company to expand its profile with the wider investment community”.

An ASX Appendix 3X for Mr. Silluzio is attached to this announcement.

Dr. Malcolm R. Brandon Chairman

Genetic Technologies Limited (ABN 17 009 212 328) Phone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtglabs.com • Email : info@gtglabs.com ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy Victoria 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone +61 3 8412 7000 • Fax +61 3 8412 7040

Appendix 3X Initial Director’s Interest Notice

Rule 3.19A.1

Appendix 3X

Initial Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity	Genetic Technologies Limited
A.B.N.	17 009 212 328

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Benjamin Silluzio
Date of appointment	10 December 2012

Part 1 - Director’s relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Number & class of securities

None

• See chapter 19 for defined terms.

Appendix 3X Page 1

11/3/2002

Appendix 3X Initial Director’s Interest Notice

Part 2 – Director’s relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

	Name of holder & nature of interestNote: Provide details of the circumstances giving rise to therelevant interest.None	Number & class of Securities

Part 3 – Director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Not applicable Nature of interest Name of registered holder (if issued securities) No. and class of securities to which interest relates

Dated: 10 December 2012

• See chapter 19 for defined terms.

Appendix 3X Page 2

11/3/2002